Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience

Eltrombopag has been used in ITP and found its use in AA armamentarium recently. We retrospectively analyzed 61 patients at a tertiary care center in Pakistan from January 2015 to January 2021. They included patients with severe AA who were refractory to at least one course of immunosuppressive ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbasi, Abdul Muqtadir, Shaikh, Mohammad Usman, Ali, Natasha, Khan, Maria, Soomar, Salman Muhammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886031/
https://www.ncbi.nlm.nih.gov/pubmed/35242527
http://dx.doi.org/10.1016/j.lrr.2022.100295
_version_ 1784660561100800000
author Abbasi, Abdul Muqtadir
Shaikh, Mohammad Usman
Ali, Natasha
Khan, Maria
Soomar, Salman Muhammad
author_facet Abbasi, Abdul Muqtadir
Shaikh, Mohammad Usman
Ali, Natasha
Khan, Maria
Soomar, Salman Muhammad
author_sort Abbasi, Abdul Muqtadir
collection PubMed
description Eltrombopag has been used in ITP and found its use in AA armamentarium recently. We retrospectively analyzed 61 patients at a tertiary care center in Pakistan from January 2015 to January 2021. They included patients with severe AA who were refractory to at least one course of immunosuppressive therapy and persistent/chronic ITP who have received at least one previous treatment for ITP. Responses to Eltrombopag in our population were comparable to real-world experiences while tolerable hepatotoxicity and GI issues were notable. We found Eltrombopag to be a safe and efficacious agent for treating patients with ITP and AA.
format Online
Article
Text
id pubmed-8886031
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-88860312022-03-02 Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience Abbasi, Abdul Muqtadir Shaikh, Mohammad Usman Ali, Natasha Khan, Maria Soomar, Salman Muhammad Leuk Res Rep Article Eltrombopag has been used in ITP and found its use in AA armamentarium recently. We retrospectively analyzed 61 patients at a tertiary care center in Pakistan from January 2015 to January 2021. They included patients with severe AA who were refractory to at least one course of immunosuppressive therapy and persistent/chronic ITP who have received at least one previous treatment for ITP. Responses to Eltrombopag in our population were comparable to real-world experiences while tolerable hepatotoxicity and GI issues were notable. We found Eltrombopag to be a safe and efficacious agent for treating patients with ITP and AA. Elsevier 2022-02-16 /pmc/articles/PMC8886031/ /pubmed/35242527 http://dx.doi.org/10.1016/j.lrr.2022.100295 Text en © 2022 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Abbasi, Abdul Muqtadir
Shaikh, Mohammad Usman
Ali, Natasha
Khan, Maria
Soomar, Salman Muhammad
Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience
title Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience
title_full Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience
title_fullStr Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience
title_full_unstemmed Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience
title_short Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience
title_sort response of eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: a single-center experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886031/
https://www.ncbi.nlm.nih.gov/pubmed/35242527
http://dx.doi.org/10.1016/j.lrr.2022.100295
work_keys_str_mv AT abbasiabdulmuqtadir responseofeltrombopaginimmunethrombocytopeniaandacquiredidiopathicaplasticanemiaasinglecenterexperience
AT shaikhmohammadusman responseofeltrombopaginimmunethrombocytopeniaandacquiredidiopathicaplasticanemiaasinglecenterexperience
AT alinatasha responseofeltrombopaginimmunethrombocytopeniaandacquiredidiopathicaplasticanemiaasinglecenterexperience
AT khanmaria responseofeltrombopaginimmunethrombocytopeniaandacquiredidiopathicaplasticanemiaasinglecenterexperience
AT soomarsalmanmuhammad responseofeltrombopaginimmunethrombocytopeniaandacquiredidiopathicaplasticanemiaasinglecenterexperience

Ejemplares similares